CAR-T cell therapy company developing curative cancer treatments for dogs using GeneWeld precision gene editing and AI protein engineering.
LEAH Labs (LifEngine Animal Health Laboratories) is the first company to achieve commercial remissions using CAR-T cell therapy in dogs with cancer, targeting B cell lymphoma. It uses the GeneWeld precision gene editing platform (invented by its founder during his PhD) and AI-driven de novo protein engineering to build affordable CAR-T therapies. Canine cancer mirrors human disease, making each dog remission a data point that accelerates human cancer therapy timelines. Clinical trials are fully funded with no cost to enrolled pet families; the next trial launches May 2026. LEAH Labs is a product of LEAH Labs.